Remove 2006 Remove Compliance Remove FDA
article thumbnail

Valencell Unveils Calibration-Free, Cuffless Blood Pressure Monitor

HIT Consultant

Founded in 2006 with a vision to help people live longer, healthier lives, Valencell’s proven inventions, sensor technology, and algorithms can be found in tens of millions of wearable and hearable devices, in over 90 products, for companies such as Samsung, Suunto, Bose, Jabra, Huawei, and Sony. Meeting Demands Under Pressure.

FDA 98
article thumbnail

Understanding the 2025 Medicare Part D Re-design: What You Need to Know

Innovaare Compliance

These changes mark a pivotal shift from its original structure in 2006. 6] A compound drug not approved by the FDA under a New Drug Application or Biological License Application does not meet the definition of an applicable drug and will not be eligible for Part D. Rebates from the selected drugs may change. Non-applicable drugs (i.e.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary 4 | Monthly Update 2021

SQA

The new regulation, RDC 478/2021 , repeals economic monitoring and reporting processes previously established under RDC 185/2006, and initially reduces the number of medical device types for which economic monitoring will be required. FDA plant inspection and pay $50 million in fines and forfeiture. 10 May 2021.

article thumbnail

SQA Regulatory Surveillance Summary 5 | Monthly Update 2021

SQA

ISO 10651-5:2006, Lung ventilators for medical use – Particular requirements for basic safety and essential performance – Part 5: Gas-powered emergency resuscitators. Led by the FDA and ASPR, the White House report and its recommendations ( report PDF ) have been accepted by President Biden. United States FDA – Guidances for Devices.

FDA 83
article thumbnail

Guest Post – Michigan Product Liability Law:  Retroactivity of New Law and Primer

Drug & Device Law

As the DDL blog has previously reported , Michigan’s longstanding presumption of non-defectiveness applicable to FDA-approved drugs was recently repealed by the Michigan legislature in S.B. As this provision is newly applicable to FDA-approved products, it has not been tested by the courts on this issue. Auto Owners Ins.

FDA 52
article thumbnail

Pretty Potent Mix In A Prescription Painkiller Preemption Decision

Drug & Device Law

2015), finally gave appellate recognition to the preemption of design defect claims for FDA-approved branded prescription drugs. FDA approved the drug with its particular formulation and the manufacturer could not have changed the formulation on its own. 2006), aff’d by equally divided court , 552 U.S. 3d 281 (6th Cir.

FDA 64
article thumbnail

Applying the Helpful but Problematic New Jersey Statute Creating a Rebuttable Compliance Presumption, the Third Circuit Affirms Dismissal of a Failure-to-Warn Claim

Drug & Device Law

2022), a short decision that came out the right way, but did so based on a problematic statute that creates a rebuttal presumption that warning labels approved by the FDA are adequate as a matter of state law. Stated differently, the rebuttal provision makes allegations and evidence of fraud on the FDA a prerequisite to state-law liability.